

## **Gujarat Credo Alumina Chemicals Private Limited**

March 31, 2020

#### **Ratings**

Facility	Amount (Rs. crore)	Ratings <sup>1</sup>	Rating Action
Long term Bank	175.00	CARE BB+; ISSUER NOT	Issuer not cooperating; Revised
Facilities		COOPERATING*	from CARE BBB-; Stable (Triple B
		(Double B Plus; ISSUER NOT	Minus; Outlook: Stable) on the
		COOPERATING*)	basis of best available
			information
Total	175.00		
	(Rupees One Hundred and		
	Seventy Five Crore only)		

Details of instruments/facilities in Annexure-1

### **Detailed Rationale& Key Rating Drivers**

CARE has been seeking information from Gujarat Credo Alumina Chemicals Private Limited (GCACPL) to monitor the rating(s) vide e-mail communications/letters dated dated January 17, 2020, February 03, 2020, February 06, 2020, February 26, 2020, March 5, 2020, March 17, 2020, March 20, 2020 and numerous phone calls. However, despite our repeated requests, the company has not provided the requisite information for monitoring the ratings. In line with the extant SEBI guidelines, CARE has reviewed the rating on the basis of the best available information which however, in CARE's opinion is not sufficient to arrive at a fair rating. Further, GCACPL has not paid the surveillance fees for the rating exercise as agreed to in its Rating Agreement. The rating on GCACPL.'s bank facilities will now be denoted as CARE BB+; Stable; ISSUER NOT COOPERATING\*.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

The ratings have been revised on account of non-availability of information and lower than envisaged sales during 9MFY20.

The rating assigned to the bank facilities of GCACPL continues to remain constrained on account of project risk in terms of stabilization of the project and achievement of envisaged level of operations and profitability, competition from established player and risk associated with lower supply of bauxite by GMDC.

The rating however continues to derive strength from its experienced promoters having long standing experience in the bauxite processing business, synergetic operations of the envisaged project under GCACPL being a forward integration of the existing operations of its group company [i.e. Gujarat Credo Mineral Industries Ltd. (GCMIL)], strategic location of its proposed manufacturing facility at Mundra SEZ and long term bauxite supply agreement of GCMIL with Gujarat Mineral Development Corporation Limited (GMDC).

### Detailed description of the key rating drivers

At the time of last rating on February 4, 2019, the followings were the rating strengths and weaknesses (updated for the information available about the project status and sales provided by the company):

## **Key Rating Weaknesses**

**Project Risk:** Project was completed on June 23, 2019 with a total cost of Rs.319.23 crore as against envisaged cost of Rs.298.05 crore. As per monthly sales information provided by the client the company has reported net sales of Rs. 24.78 crore till December 31, 2019 which is relatively lower than envisaged levels. There is a project stabilization risk in terms of achievement of envisaged Total Operating Income (TOI) and profitability.

**Strong competition from established player in the market**: In India, Hindalco is the single largest player which has dominant domestic market share of 80%-90% which allows it to dictate prices & quantities to be sold and hence it is likely to act as a strong competitor for GCACPL once its manufacturing facility is operational.

**Risk associated with lower than required raw bauxite supply by GMDC**: Project of GCACPL being a forward integration would critically depend on supply of beneficiated bauxite from GCMIL and in turn supply of beneficiated bauxite from

 $^1$ Complete definitions of the ratings assigned are available at <u>www.careratings.com</u> and in other CARE publications.



GCMIL would depend on required supply of raw bauxite by GMDC. During FY19, there had been lower than required raw bauxite supply by GMDC to GCMIL due to some mining related issues at the end of GMDC despite its long-term bauxite supply agreement with it. Going forward required supply of raw bauxite from GMDC would be critical.

### **Key Rating Strengths**

Experienced promoters with track record in similar line of business: GCACPL is a wholly owned subsidiary of Credo Mineral Industries Ltd (CMIL), which has resourceful promoters. As on March 31, 2019, CMIL on a standalone basis had a net worth of Rs. 167 crore. Gujarat Apollo Industries Ltd. (Gujarat Apollo) which holds ~23% stake in CMIL, had a net worth of Rs. 477 crore on a consolidated basis as on March 31, 2019 with negligible debt on its books. Chem Asia Technologies Pte Ltd. (Chem Asia) has invested funds in CMIL wherein it holds 12.24% stake as on March 31, 2019 against exclusive right of 25% of production of GCACPL. The balance equity in CMIL is held by promoters of Credo group alongwith their family members and few HNIs. GCMIL (rated CARE BBB+; Stable/ CARE A2), a group company of GCACPL, is engaged in related field of manufacturing of beneficiated bauxite for the last five years.

Availability of long term raw bauxite supply agreement between GMDC and GCMIL: GMDC is a GoG owned company, having huge reserves of bauxite in the state of Gujarat. GCMIL has a long term bauxite supply agreement with GMDC to meet its requirement. This arrangement with GMDC for raw bauxite supply imparts competitive edge to the operations of GCMIL from which even GCACPL is envisaged to benefit as it is envisaged to be an extension of the operations of GCMIL.

**Location advantage of setting up manufacturing plant at Mundra SEZ**: Manufacturing facility of GCACPL is to be strategically located at Mundra SEZ which will give huge logistic advantage to its export business. In addition, GCACPL would also benefit from various SEZ exemptions available in the form of Taxes, cess, duties, etc.

Analytical approach: Standalone

### **Applicable Criteria:**

Policy in respect of Non-cooperation by issuer
Criteria on assigning Outlook to Credit Ratings
CARE's Policy on Default Recognition
Rating Methodology-Manufacturing Companies
Financial ratios – Non-Financial Sector
Rating Methodology - Factoring Linkages in Ratings

## **About the Company**

Incorporated on May 14, 2016 to setup a forward integration project to manufacture different grades of ATH, GCACPL (CIN: U14290GJ2016PTC092013) is wholly owned subsidiary of CMIL. Beneficiated bauxite manufactured by its group company viz. GCMIL would be used as a raw material by GCACPL for manufacturing ATH. GCACPL's manufacturing facility would be located at Mundra Special Economic Zone (SEZ), Gujarat with an installed capacity of 65,000 MTPA. The company incurred a project cost of Rs. 319 crore which was funded by equity of Rs. 123 crore, unsecured loans amounting to Rs. 10 crore, term loans from banks amounting to Rs. 143 crore and creditors amounting to Rs. 43 crore. The project started commercial production on June 23, 2019.

Brief Financial: Not applicable as company started commercial production in June 2020.

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating History for last three years: Please refer Annexure-2

# Annexure-1: Details of Instruments/Facilities

Name of the	Date of	Coupon	Maturity	Size of the Issue	Rating assigned along with Rating		
Instrument	Issuance	Rate	Date	(Rs. crore)	Outlook		
Fund-based - LT-Term Loan	-	-	March, 2029		CARE BB+; Stable; ISSUER NOT COOPERATING* Issuer not cooperating; Revised from CARE BBB-; Stable on the basis of best available information		

<sup>\*</sup>Issuer did not cooperate; Based on best available information



### Annexure-2: Rating History of last three years

Sr.	Sr. Name of the		Current Ratings			Rating history			
No.	Instrument/Bank	Туре	Amount	Rating	Date(s) &	Date(s) &	Date(s) &	Date(s) &	
	Facilities		Outstanding		Rating(s)	Rating(s)	Rating(s)	Rating(s)	
			(Rs. crore)		assigned in	assigned in	assigned in	assigned in	
					2019-2020	2018-2019	2017-2018	2016-2017	
1.	Fund-based - LT-Term	LT	175.00	CARE BB+; Stable;	-	1)CARE	1)CARE	-	
	Loan			ISSUER NOT		BBB-;	BBB-;		
				COOPERATING*		Stable	Stable		
				Issuer not		(04-Feb-19)	(14-Nov-17)		
				cooperating; Revised					
				from CARE BBB-;					
				Stable on the basis of					
				best available					
				information					

<sup>\*</sup>Issuer did not cooperate; Based on best available information

**Note on complexity levels of the rated instrument:** CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.

### **CONTACT US**

### **Media Contact**

Mr. Mradul Mishra

Contact No.: +91-22-6837 4424

Email ID - mradul.mishra@careratings.com

### **Analyst Contact**

Mr. Akhil Goyal

Contact No.: +91-79-4026 5621 Email ID – <u>akhil.goyal@careratings.com</u>

## **Relationship Contact**

Mr. Deepak Prajapati

Contact No.: +91-79-4026 5656

Email ID - deepak.prajapati@careratings.com

### **About CARE Ratings:**

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.



### Disclaimer

CARE's ratings are opinions on credit quality and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments.

In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

<sup>\*\*</sup>For detailed Rationale Report and subscription information, please contact us at www.careratings.com